Review



topscience preclinical compound library  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    TargetMol topscience preclinical compound library
    Topscience Preclinical Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Preclinical+Compound+Library/ppr0759270-52-17-17
    Average 93 stars, based on 4 article reviews
    topscience preclinical compound library - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Drug discovery:

    Article Title: Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma.
    Article Snippet: .. Four separate drug libraries were selected, specifically with a drug re-purposing context in mind, and included pre-clinical and/or FDA-approved compounds: the TargetMol anticancer set (L2110, 330 compounds), Kinase Chemogenomic set (KCGS [39], 187 compounds), LOPAC (1280 compounds, Merck), and a custom chemogenomic library set (789 compounds, ‘Comprehensive anti-Cancer small Compound Library, or C3L) [34], with dosing across four concentrations (1000, 300, 100, 30 nM). .. Four separate drug libraries were selected, specifically with a drug re-purposing context in mind, and included pre-clinical and/or FDA-approved compounds: the TargetMol anticancer set (L2110, 330 compounds), Kinase Chemogenomic set (KCGS [39], 187 compounds), LOPAC (1280 compounds, Merck), and a custom chemogenomic library set (789 compounds, ‘Comprehensive anti-Cancer small Compound Library, or C3L) [34], with dosing across four concentrations (1000, 300, 100, 30 nM).

    Article Title: π‐PhenoDrug: A Comprehensive Deep Learning‐Based Pipeline for Phenotypic Drug Screening in High‐Content Analysis
    Article Snippet: .. The melanoma cell line A375 was treated with a library containing 80 bioactive compounds from an FDA-approved kinase inhibitor library (TargetMol Chemicals Inc., L1610), a chemical drug library (TargetMol Chemicals Inc., L2151), and a preclinical compound library (TargetMol Chemicals Inc., L3410) at a concentration of 1.0 μM for all drugs. ..

    Article Title: Identification of a novel small molecule to inhibit gastric cancer cells growth
    Article Snippet: .. CCK-8 assay was rstly applied to assess the growth inhibitory effects of 10 μM compound from the Topscience Preclinical Compound Library (Catalog No.L3410, 450 compounds) against gastric cancer AGS cells. ..

    Concentration Assay:

    Article Title: π‐PhenoDrug: A Comprehensive Deep Learning‐Based Pipeline for Phenotypic Drug Screening in High‐Content Analysis
    Article Snippet: .. The melanoma cell line A375 was treated with a library containing 80 bioactive compounds from an FDA-approved kinase inhibitor library (TargetMol Chemicals Inc., L1610), a chemical drug library (TargetMol Chemicals Inc., L2151), and a preclinical compound library (TargetMol Chemicals Inc., L3410) at a concentration of 1.0 μM for all drugs. ..

    CCK-8 Assay:

    Article Title: Identification of a novel small molecule to inhibit gastric cancer cells growth
    Article Snippet: .. CCK-8 assay was rstly applied to assess the growth inhibitory effects of 10 μM compound from the Topscience Preclinical Compound Library (Catalog No.L3410, 450 compounds) against gastric cancer AGS cells. ..



    Similar Products

    95
    TargetMol clinical stage compounds
    Clinical Stage Compounds, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/10__1021_slash_acs__jmedchem__6c01726-423-7-11
    Average 95 stars, based on 1 article reviews
    clinical stage compounds - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals natural terpenoid compound library
    Primary screening of a <t>terpenoid</t> <t>compound</t> <t>library</t> against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.
    Natural Terpenoid Compound Library, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Compound/pmc13748739-35-1-11
    Average 96 stars, based on 1 article reviews
    natural terpenoid compound library - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    90
    TargetMol anti cardiovascular disease compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Anti Cardiovascular Disease Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Anti-Cardiovascular+Disease+Compound+Library/pmc13748904-58-22-21
    Average 90 stars, based on 1 article reviews
    anti cardiovascular disease compound library - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    96
    TargetMol pharmacopeia compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Pharmacopeia Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/FDA-Approved+Drug+Library/10__1038_slash_s41419___026___09401___w-74-10-7
    Average 96 stars, based on 1 article reviews
    pharmacopeia compound library - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    TargetMol compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Clinical+Compound+Library/pm42966158-42-0-11
    Average 95 stars, based on 1 article reviews
    compound library - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    97
    TargetMol custom bioactive compound library
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Custom Bioactive Compound Library, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Bioactive+Compound+Library/pm42933337-145-13-17
    Average 97 stars, based on 1 article reviews
    custom bioactive compound library - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    94
    Selleck Chemicals organoid based drug screening
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Organoid Based Drug Screening, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Epigenetics+Compound+Library/pmc13683295-285-4-13
    Average 94 stars, based on 1 article reviews
    organoid based drug screening - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol drug screen
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Drug Screen, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Cell+Cycle+Compound+Library/pm42901431-305-15-20
    Average 94 stars, based on 1 article reviews
    drug screen - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    TargetMol endoplasmic reticulum er stress
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Endoplasmic Reticulum Er Stress, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Endoplasmic+Reticulum+Stress+Compound+Library/pm42896314-137-3-21
    Average 94 stars, based on 1 article reviews
    endoplasmic reticulum er stress - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    96
    TargetMol ferroptosis
    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the <t>TargetMol</t> <t>Anti‐Cardiovascular</t> Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Ferroptosis, supplied by TargetMol, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+libraries/Ferroptosis+Compound+Library/pm42896314-137-8-21
    Average 96 stars, based on 1 article reviews
    ferroptosis - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

    Journal: JAC-Antimicrobial Resistance

    Article Title: Identification of valepotriate as a novel antimycobacterial agent against drug-resistant Mycobacterium tuberculosis through screening of a natural terpenoid compound library

    doi: 10.1093/jacamr/dlag250

    Figure Lengend Snippet: Primary screening of a terpenoid compound library against M. tb H37Rv. M. tb H37Rv was cultured in Middlebrook 7H9 medium supplemented with OADC and exposed to individual terpenoid compounds at a final concentration of 20 μM for 14 days. Bacterial growth was assessed by OD 600 measurement, and compounds showing marked growth inhibition were identified as primary hits. Untreated bacteria served as the negative control, whereas INH-treated bacteria served as the positive control. Data represent the mean of three independent experiments.

    Article Snippet: A natural terpenoid compound library containing 354 compounds was purchased from Selleck Chemicals (L1420, Selleck Chemicals, USA).

    Techniques: Screening, Drug discovery, Cell Culture, Concentration Assay, Inhibition, Bacteria, Negative Control, Positive Control

    Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: Advanced Science

    Article Title: Targeting a Calcium‐Associated Mitochondrial Vulnerability in TET2‐Deficient Myeloid Cells

    doi: 10.1002/advs.78748

    Figure Lengend Snippet: Chemical‐genetic screening identifies Lanatoside C as a selective inhibitor of TET2 ‐KD macrophages. (A) Screening workflow for identifying compounds preferentially targeting TET2‐KD macrophages. siScr and siTET2 THP‐1‐derived macrophages were plated in 384‐well format and treated with 489 compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library for 48 h. Viability was measured by Alamar Blue and normalized to genotype‐matched DMSO controls. Hits were selected based on preservation of siScr viability > 80% and reduction of siTET2 viability < 70%, followed by secondary validation and prioritization of Lanatoside C. (B) Heatmap of relative cell viability in siScr or siTET2 macrophages treated with 489 cardiovascular disease‐related bioactive compounds (10 µM, 48 h). Viability was assessed by Alamar Blue and expressed relative to the corresponding genotype‐matched vehicle controls. n = 4 biologically independent replicates per treatment. (C) Quantification of cell viability by Alamar Blue assay in siScr or siTET2 macrophages treated with vehicle or a subset of 8 selected compounds. n = 8 biologically independent replicates per condition. (D) Quantification of proliferation‐associated metabolic activity using the MTS assay in siScr or siTET2 macrophages treated with vehicle or the same subset of 8 selected compounds. n = 4 biologically independent replicates per condition. (E) Quantification of cleaved‐Caspase‐3‐positive macrophages treated with siScr or siTET2, vehicle (DMSO), or Lanatoside C. n = 4 biologically independent replicates per treatment. (F) Quantification of cell viability by Trypan Blue exclusion in macrophages treated as in (E). n = 4 biologically independent replicates per condition. (G) Quantification of EdU‐positive macrophages treated with siScr or siTET2, vehicle, or Lanatoside C. n = 8 biologically independent replicates per condition. (H–J) Relative IL‐1β, IL‐6, and IL‐18 levels in macrophage monocultures following siScr or siTET2 transfection and treatment with vehicle or Lanatoside C. Cytokines were measured by ELISA and normalized to the siScr Vehicle group. Lanatoside C reduced the elevated inflammatory cytokine levels observed in TET2‐KD macrophages. n = 5 biologically independent replicates per condition. (K) UMAP plots from RNA sequencing of macrophages treated with siScr or siTET2 and vehicle or Lanatoside C. Each biological replicate comprised one million macrophages; n = 3 biologically independent replicates per condition. Data are shown as mean ± SEM. For the quantitative validation experiments in (C‐J), statistical significance was assessed using two‐way ANOVA followed by Tukey's multiple‐comparisons test, with the indicated pairwise comparisons shown in the figure. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: To identify compounds that preferentially compromise TET2 ‐KD macrophages, we performed chemical‐genetic screening using 489 cardiovascular disease‐related bioactive compounds from the TargetMol Anti‐Cardiovascular Disease Compound Library (Figure and Extended Data Table ).

    Techniques: Screening, Derivative Assay, Drug discovery, Preserving, Biomarker Discovery, Alamar Blue Assay, Activity Assay, MTS Assay, Transfection, Enzyme-linked Immunosorbent Assay, RNA Sequencing